Search Results - "Thompson, D.D."

Osteopenia and impaired fracture healing in aged EP4 receptor knockout mice by Li, M., Healy, D.R., Li, Y., Simmons, H.A., Crawford, D.T., Ke, H.Z., Pan, L.C., Brown, T.A., Thompson, D.D.

“…The EP4 receptor, one of the subtypes of the prostaglandin E 2 (PGE 2) receptor, plays a critical role in the anabolic effects of PGE 2 on bone. However, its…”
Get full text

The efficacy of a locally injectable prostaglandin EP-2 receptor agonist on fracture healing by Thompson, D.D, Kaplan, I.V, Paralkar, V.M, Buljat, G, Sanders, D, Schwappach, J, Bhandari, M, Vukicevic, S

Get full text

The response of bone turnover markers to lasofoxifene: The PEARL trial by Eastell, R, Reid, D.M, Vukicevic, S, Delmas, P.D, Thompson, J, Thompson, D.D, Cummings, S.R

Get full text

Effects of gestational age on prostaglandin EP receptor expression and functional involvement during in vitro contraction of the guinea pig uterus by Terry, K.K, Lebel, W.S, Riccardi, K.A, Grasser, W.A, Thompson, D.D, Paralkar, V.M

“…Abstract Prostaglandin E2 (PGE2 ) exerts diverse biological effects through four G-protein-coupled cell surface receptor subtypes, EP1–4. This study's…”
Get full text

Regulation of BMP-7 expression by retinoic acid and prostaglandin E2 by Paralkar, V.M., Grasser, W.A., Mansolf, A.L., Baumann, A.P., Owen, T.A., Smock, S.L., Martinovic, S., Borovecki, F., Vukicevic, S., Ke, H.Z., Thompson, D.D.

“…Bone morphogenetic proteins (BMPs) are members of the transforming growth factor‐beta (TGF‐β) gene superfamily of growth and differentiation factors. Members…”
Get full text

Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model by Ke, H.Z., Chen, H.K., Simmons, H.A., Qi, H., Crawford, D.T., Pirie, C.M., Chidsey-Frink, K.L., Ma, Y.F., Jee, W.S.S., Thompson, D.D.

“…The purpose of this study was to compare the effects of droloxifene (DRO), tamoxifen (TAM), and 17α-ethynyl estradiol (EE) on bone mineral density, bone…”
Get full text

Role of EP2 and EP4 receptor-selective agonists of prostaglandin E2 in acute and chronic kidney failure by Vukicevic, S., Simic, P., Borovecki, F., Grgurevic, L., Rogic, D., Orlic, I., Grasser, W.A., Thompson, D.D., Paralkar, V.M.

“…We tested the efficacy of three selective agonists of prostaglandin E2 (PGE2) receptor, EP2 (CP-536,745-01), EP2/4 (CP-043,305-02), and EP4 (CP-044,519-02), in…”
Get full text

Indomethacin inhibition of tenotomy‐induced bone resorption in rats by Thompson, D.D., Rodan, G.A.

“…Loss of biomechanical function results in rapid bone loss. This study assesses the role of arachidonic acid metabolites in immobilization‐related osteopenia. A…”
Get full text

The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons by Thompson, D.D., Seedor, J.G., Quartuccio, H., Solomon, H., Fioravanti, C., Davidson, J., Klein, H., Jackson, R., Clair, J., Frankenfield, D., Brown, E., Simmons, H.A., Rodan, G.A.

“…We examined the effect of the amino bisphosphonate alendronate, administered IV every 2 weeks at 0.05 and 0.25 mg/kg for 1 year, on bone loss and parameters…”
Get full text

FDA guidelines and animal models for osteoporosis by THOMPSON, D. D, SIMMONS, H. A, PIRIE, C. M, KE, H. Z

“…The recent FDA Guidelines For Preclinical and Clinical Evaluation of Agents Used in the Treatment or Prevention of Postmenopausal Osteoporosis (1994) delineate…”
Get full text

Regulation of BMP‐7 expression by retinoic acid and prostaglandin E 2 by Paralkar, V.M., Grasser, W.A., Mansolf, A.L., Baumann, A.P., Owen, T.A., Smock, S.L., Martinovic, S., Borovecki, F., Vukicevic, S., Ke, H.Z., Thompson, D.D.

“…Abstract Bone morphogenetic proteins (BMPs) are members of the transforming growth factor‐beta (TGF‐β) gene superfamily of growth and differentiation factors…”
Get full text

Osteopenia in the immobilized rat hind limb is associated with increased bone resorption and decreased bone formation by Weinreb, M, Rodan, G A, Thompson, D D

“…The lack of mechanical function (disuse) caused by paralysis, immobilization or weightlessness, leads to osteopenia. This study examines the contribution of…”
Get more information

Prostaglandin E2 increases bone strength in intact rats and in ovariectomized rats with established osteopenia by Ke, H.Z, Shen, V.W, Qi, H, Crawford, D.T, Wu, D.D, Liang, X.G, Chidsey-Frink, K.L, Pirie, C.M, Simmons, H.A, Thompson, D.D

“…It is well documented that prostaglandin E2 (PGE2) has the ability to stimulate bone formation, improve bone structure, and increase bone mass in intact or…”
Get full text

Droloxifene and estrogen inhibit osteoclast development in-vitro by Paralkar, V.M., Grasser, W.A., Thompson, D.D.

Get full text

Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats by KE, H. Z, CHEN, H. K, QI, H, PIRIE, C. M, SIMMONS, H. A, MA, Y. F, JEE, W. S. S, THOMPSON, D. D

“…The purpose of this study was to determine the efficacy of droloxifene (DRO), an estrogen antagonist/agonist, in preventing ovariectomy (OVX)-induced lumbar…”
Get full text

Droloxifene does not blunt bone anabolic effects of prostaglandin E 2, but maintains prostaglandin E 2-restored bone in aged, ovariectomized rats by Ke, H.Z, Crawford, D.T, Qi, H, Pirie, C.M, Simmons, H.A, Chidsey-Frink, K.L, Chen, H.K, Jee, W.S.S, Thompson, D.D

“…Droloxifene (DRO) is a selective estrogen receptor modulator that prevents bone loss by inhibition of bone turnover associated with estrogen deficiency in both…”
Get full text

CP-336,156, a new estrogen agonist/antagonist, inhibits bone turnover and prevents bone loss in ovariectomized rats by Ke, H.Z., Qi, H., Crawford, D.T., Chidsey-Frink, K.L., Simmons, H.A., Pirie, C.M., Thompson, D.D.

Get full text

Longitudinal and cross-sectional characterization of long-term skeletal effects of aging and orchidectomy in the male rat by Ke, H.Z., Qi, H., Crawford, D.T., Pirie, C.M., Simmons, H.A., Thompson, D.D.

Get full text

Droloxifene does not blunt bone anabolic effects of prostaglandin E2, but maintains prostaglandin E2-restored bone in aged, ovariectomized rats by KE, H. Z, CRAWFORD, D. T, QI, H, PIRIE, C. M, SIMMONS, H. A, CHIDSEY-FRINK, K. L, CHEN, H. K, JEE, W. S. S, THOMPSON, D. D

“…Droloxifene (DRO) is a selective estrogen receptor modulator that prevents bone loss by inhibition of bone turnover associated with estrogen deficiency in both…”
Get full text

Common mechanism for the estrogen agonist and antagonist activities of droloxifene by Grasser, W. A., Pan, L. C., Thompson, D.D., Paralkar, V.M.

“…The incidence of postmenopausal osteoporosis is increasing as the population ages. Even though estrogen replacement therapy has proven beneficial in reducing…”
Get full text